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The cucurbit[n]uril (CB[n]) family of macrocycles has been shown to have potential in drug
delivery where they are able to provide physical and chemical stability to drugs, improve drug
solubility, control drug release and mask the taste of drugs. Cisplatin is a small molecule
platinum-based anticancer drug that has severe dose-limiting side-eﬀects. Cisplatin forms a
host–guest complex with cucurbit[7]uril (cisplatin@CB[7]) with the platinum atom and both
chlorido ligands located inside the macrocycle, with binding stabilised by four hydrogen bonds
(2.15–2.44 A˚). Whilst CB[7] has no eﬀect on the in vitro cytotoxicity of cisplatin in the human
ovarian carcinoma cell line A2780 and its cisplatin-resistant sub-lines A2780/cp70 and MCP1,
there is a signiﬁcant eﬀect on in vivo cytotoxicity using human tumour xenografts.
Cisplatin@CB[7] is just as eﬀective on A2780 tumours compared with free cisplatin, and in the
cisplatin-resistant A2780/cp70 tumours cisplatin@CB[7] markedly slows tumour growth. The
ability of cisplatin@CB[7] to overcome resistance in vivo appears to be a pharmacokinetic eﬀect.
Whilst the peak plasma level and tissue distribution are the same for cisplatin@CB[7] and free
cisplatin, the total concentration of circulating cisplatin@CB[7] over a period of 24 hours is
signiﬁcantly higher than for free cisplatin when administered at the equivalent dose. The results
provide the ﬁrst example of overcoming drug resistance via a purely pharmacokinetic eﬀect rather
than drug design or better tumour targeting, and demonstrate that in vitro assays are no longer as
important in screening advanced systems of drug delivery.
Introduction
Platinum-based drugs represent the major class of agents in
chemotherapy for the treatment of a range of human cancers
including: testicular, head and neck, colorectal, bladder, lung and
ovarian.1,2 Cisplatin was the ﬁrst drug approved in this class and
after 40 years remains in use, but clinical activity is limited by
systemic toxicity and tumour drug resistance (Fig. 1).1 A number
of platinum analogues have been developed in an attempt to
improve the therapeutic eﬃcacy of cisplatin.1 The introduction of
carboplatin resulted in a signiﬁcant reduction in the nephrotoxicity
associated with platinum-based chemotherapy.2 Oxaliplatin, a
recently approved platinum based drug, is used primarily in the
treatment of colorectal cancer; a tumour type previously resistant
to cisplatin treatment.2 New drugs continue to be developed,
Fig. 1 The chemical structures of cucurbit[7]uril (CB[7]) and cisplatin.
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such as the multinuclear drug BBR3464,3,4 orally active drugs
like satraplatin and sterically hindered drugs like picoplatin.1,2
Advances in drug delivery, however, can also be exploited to
improve the clinical eﬃcacy of anticancer drugs. The delivery
of platinum drugs can be improved through their encapsulation
in macrocycles, polymers or liposomes. Use of these vehicles
protects the drugs from binding to serum proteins whilst in
circulation, and allows the drugs to be better targeted to tumours
through the enhanced permeability and retention eﬀect.5
Cucurbit[n]urils (CB[n], Fig. 1) are a family of rigid macro-
cycles made from the acid condensation of glycoluril and
formaldehyde.6,7 They have a hydrophobic cavity, accessible
through two hydrophilic oxygen lined portals, and are capable
of storing and releasing small molecules.8,9 Encapsulation of a
drug molecule by cucurbituril can provide a range of beneﬁts
including: chemical10–12 and thermal stability,13–15 improved
drug solubility,16,17 controlled drug release,18,19 and potential taste
masking of some drugs.14 Cucurbiturils of all sizes have been shown
to be non-cytotoxic and non-toxic,10,20 and can be formulated into
dosage forms suitable for human drug administration.9,21
In this paper we report for the ﬁrst time the use of
cucurbiturils to enhance the cytotoxicity, and overcome drug
resistance, of a platinum anticancer agent via a purely phar-
macokinetic eﬀect. The mode of cisplatin encapsulation by
CB[7] has been investigated using molecular modeling and the
eﬀect of the macrocycle on the drug’s in vitro and in vivo
cytotoxicity determined using matched human ovarian carcinoma
cell lines. The whole body pharmacokinetic eﬀect of CB[7] has
also been examined in vivo and assessed to determine peak drug
serum concentration times and uptake of the drug into diﬀerent
vital organs.
Results and discussion
Molecular modelling
Cucurbiturils form a range of host–guest complexes with
drugs by two possible complementary modes utilising hydro-
phobic interactions between the cavity of the macrocycle and a
drug and/or ion–dipole or dipole–dipole interactions (hydrogen
bonding) between the cucurbituril carbonyl groups and drug
am(m)ine groups.9 For platinum-based drugs that have organic
ligands, like oxaliplatin or multinuclear drugs, the association
constant of the host–guest complex can be relatively high
(105 M1), although the strength of binding and the rate of
drug release can be controlled by varying the size of the
cucurbituril used.10 Whilst we have previously shown that
cisplatin can form host–guest complexes with CB[7],22 the
nature of the binding has not been examined. How the drug
binds to cucurbiturils is important as cisplatin has no organic
ligand with which it can utilise hydrophobic interactions with
the macrocycle’s cavity. As such, binding may be quite weak and
the drug easily dissociated when dissolved at pharmaceutically
relevant concentrations.
Molecular models of cisplatin with CB[7] were generated,
with the cisplatin positioned pointing into the macrocycle, and
alternatively, with cisplatin positioned at the edge of the
cucurbituril pointing out from the macrocycle (Fig. 2a); two
modes that have been predicted from 1H and 195Pt NMR spectra.22
In the pointing in position the platinum atom and the two
chlorido ligands of the drug are located within the CB[7]
cavity, where steric hindrance provides protection of the drug from
attack from potential biological nucleophiles, like glutathione,
and proteins containing accessible cysteine and methionine
residues.12,23,24 In this case, binding into the cavity is stabilised
by four hydrogen bonds, with lengths of between 2.15 and
2.44 A˚ (Fig. 2b).
In the pointing out mode of cisplatin binding, the distance
between the drug ammine hydrogen atoms and the CB[7]
carbonyl oxygen atoms is too great to form hydrogen bonds
properly; 2.60 to 3.40 A˚. Binding in this manner is also less
energetically favourable compared with the pointing in mode
of binding by 0.961 kJ mol1. Attempts to measure the
association constant of cisplatin to CB[7] using ﬂuorescent
displacement assays of methylene-blue were unsuccessful and
indicate that the Kb is less than 10
4 M1. The results therefore
clearly indicate a preferred mode of binding by the drug in
which it is pointing into the cavity of CB[7], which is potentially
useful in drug delivery.
In vitro cytotoxicity
The ovarian cell line A2780 is relatively sensitive to cisplatin. It
has a functional wild type p53 gene and expresses the MLH1
component of the DNA mismatch repair pathway. This pathway
has been shown to be involved in the recognition of cisplatin–DNA
Fig. 2 (a) Molecular models of the host–guest complexes of the
anticancer drug cisplatin with cucurbit[7]uril, showing the two
potential modes of binding: pointing in, where the platinum atom
and chlorido ligands are located within the macrocycle’s cavity and
pointing out, where binding occurs only at the CB[7] portals and is less
energetically favourable. (b) A molecular model of the pointing in
mode of binding of cisplatin to CB[7] showing the four hydrogen
bonds from the drug’s ammine hydrogen atoms to the macrocycle’s
carbonyl oxygen atoms (bond lengths: 2.15, 2.22, 2.38 and 2.44 A˚) that
stabilise the host–guest complex.
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adducts and induction of apoptosis.25–27 Loss of the mismatch
repair (MMR) enzyme function results in resistance in vitro to
a number of clinically important anticancer drugs, including
cisplatin and doxorubicin,28–30 and has been associated with
selection for drug-resistant breast and ovarian tumours during
chemotherapy.29,31 A2780/cp70 and MCP1 are cisplatin resistant
cell lines derived from A2780 that lack MLH1 and are 27- and
3-fold resistance to cisplatin in vitro, respectively. Re-expression
of MLH1 sensitises xenografts of A2780/cp70 to cisplatin.32
The in vitro growth inhibition assay is the gold standard as a
ﬁrst screening tool when evaluating new drug candidates.
A compound which has a high IC50 (the concentration of
drug required to inhibit cell growth by 50%) is not generally
further developed. The IC50 of cisplatin is dependent on the cell
line used and the length of exposure of the drug to the cells, but is
usually somewhere between 0.1 and 10 mM. Therefore a new
platinum drug candidate in the past has needed an IC50 in the sub-
micromolar concentration range to warrant further development.
Encapsulation of cisplatin in CB[7] (cisplatin@CB[7]) had
no eﬀect on the cytotoxicity of the drug in the A2780 cell line
and had no eﬀect on the resistance of A2780/cp70 and MCP1
(Table 1). Similarly, p53 was induced 24 hours after treatment
of cells with either free cisplatin or cisplatin@CB[7] and
showed the same dose dependent increase in the two cell lines
with wild type p53 (A2780 and MCP1; Fig. 3A). The induction
of apoptosis, as measured by the appearance of an 85 kDa
cleavage product of poly ADP ribose polymerase, also showed
the same dose dependence for free cisplatin and cisplatin@CB[7]
(Fig. 3B).
In some instances, encapsulation of platinum drugs within
diﬀerent sized CB[n]s has led to a large increase in IC50, or
complete loss of in vitro cytotoxicity.10,24 Previously, we and
others have speculated that the decrease in in vitro cytotoxicity
of some platinum drugs upon encapsulation in CB[n]s was due
to either decreased cell uptake or because the drugs were too
strongly bound by the CB[n] and could not go on to bind
DNA at a suﬃciently fast rate.10,33,34 In only a few instances
has encapsulation by CB[6] increased the cytotoxicity of some
platinum(II)-based DNA intercalator drugs.34,35 Ordinarily,
the lack of change in in vitro cytotoxicity of cisplatin upon
encapsulation within CB[7] would not warrant further testing,
although recent research with other drug delivery vehicles has
demonstrated a lack of correlation between in vitro and in vivo
results when testing drug delivery systems.36 On this basis free
cisplatin and cisplatin@CB[7] were also examined using in vivo
models.
In vivo cytotoxicity
Intraperitoneal injection (i.p.) of CB[7] alone is well tolerated
in nude mice and a dose of 250 mg kg1 had no eﬀect on the
tumour growth rates of either A2780 or A2780/cp70 xenografts
or on the weight of the animals. Tumours of A2780 are sensitive
to cisplatin (i.p.) and show a signiﬁcant growth delay when
treated with cisplatin (P o 0.001, Table 2 and Fig. 4A).
Treatment with cisplatin@CB[7] (i.p.) at an equivalent dose
resulted in a slightly increased growth delay (P o 0.005).
Surprisingly, the xenografts of A2780/cp70, which are resistant
to the maximum tolerated dose (MTD) of cisplatin (6 mg kg1),
are sensitive to cisplatin@CB[7] (34 mg kg1; which yields
6 mg kg1 of cisplatin) with a tumour doubling time 1.6-fold
that of free cisplatin (Po 0.001, Table 2 and Fig. 4B). Neither
of the platinum treatments had any signiﬁcant eﬀect on the
body weight of the mice (results not shown).
Since CB[7] encapsulation had no eﬀect on the in vitro
cytotoxicity of cisplatin the increased activity in the resistant
xenograft model suggests that encapsulation has altered the
bioavailability of the drug. Previously, we hypothesised that
the main beneﬁt of CB[n] encapsulation of platinum drugs
would be from steric hindrance that prevents degradation and
deactivation by thiols.12,23,33 As an increase in glutathione
levels is not a major mechanism of resistance in A2780/cp70
cells, and the fact that encapsulation did not result in a higher
MTD of cisplatin (as would have been expected if serum
protein binding was reduced), the results imply that some
other pharmacokinetic eﬀect, such as altered drug distribution
to the tumour, is responsible for the enhanced in vivo activity.
Plasma and tissue pharmacokinetics
Plasma levels of platinum were measured at various times after a
single i.p. dose of either cisplatin (6 mg kg1) or cisplatin@CB[7]
Table 1 In vitro cytotoxicity of free cisplatin and cisplatin@CB[7] in
the human ovarian cancer cell line A2780 and its cisplatin-resistant
derivatives: A2780/cp70 and MCP1. IC50 is deﬁned as the concen-
tration of drug required to inhibit cell growth by 50%
Cell line
IC50/mM
Cisplatin Cisplatin@CB[7]
A2780 0.11  0.01 0.09  0.01
A2780/cp70 3.01  0.09 2.73  0.21
MCP1 0.34  0.01 0.35  0.08
Fig. 3 (A) The induction of p53 expression and (B) PARP cleavage
by free cisplatin and cisplatin@CB[7] in A2780 cells demonstrating no
diﬀerence in the action of either drug.
Table 2 The amount of time required for the human tumour
xenografts in nude mice to double in volume following treatment on
day 0 by intraperitoneal injection with either control (saline), CB[7],
free cisplatin or cisplatin@CB[7]
Treatment
Tumour doubling time/days
A2780 A2780/cp70
Control 3.1  0.1 3.2  0.3
CB[7] 2.9  0.2 3.2  0.4
Cisplatin 4.9  0.2 3.8  0.6
Cisplatin@CB[7] 6.3  0.5 5.3  0.2
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(34 mg kg1, Fig. 5A). The peak plasma level was observed
5 minutes after injection and this level was higher following
injection of free cisplatin than for cisplatin@CB[7]. Plasma
platinum levels decreased rapidly, but the decline was slower
for cisplatin@CB[7] such that after 15 minutes, plasma levels
of platinum were higher for cisplatin@CB[7] compared with
free cisplatin. This diﬀerence was maintained for up to
24 hours to the extent that the total area under the curve
(AUC) was signiﬁcantly lower for cisplatin (16.3 h mg mL1)
than for cisplatin@CB[7] (28.8 h mg mL1) (Table 3). Injection
of cisplatin at 8 mg kg1 resulted in a higher peak plasma level
compared to a 6 mg kg1 dose of free cisplatin (Fig. 5B).
The AUC for the ﬁrst hour after injection (AUC0–1h) was
4.2 h mg mL1 for free cisplatin at a dose of 6 mg kg1 which
increased to 4.9 h mg mL1 at a dose of 8 mg kg1, which was
similar to that obtained for cisplatin@CB[7] (4.8 h mg mL1).
The AUC over the ﬁrst 6 hours after injection was higher for
cisplatin@CB[7] (13.2 h mg mL1) than for cisplatin at either
6 mg kg1 (7.6 h mg mL1) or 8 mg kg1 (10.6 h mg mL1)
(Table 4).
The dose limiting toxicity of cisplatin is associated with the
peak plasma drug level. For the drug sensitive A2780 xenograft a
clear dose response to treatment is observed,37 but the MTD of
cisplatin is 6 mg kg1 in our mice. A comparison of plasma
platinum levels shows that the peak plasma level is increased
(from 16.2 to 19.3 mg mL1) when the dose is increased from 6 to
8 mg kg1 (Fig. 5B). The peak plasma platinum level observed
following treatment with cisplatin@CB[7] (10.4 mg mL1) is
lower than that for the free drug (16.2 mg mL1) but the
AUC0–24, a measure of the drug exposure over the ﬁrst 24 hour
after treatment, for cisplatin@CB[7] was 28.8 h mg mL1,
nearly double that for free cisplatin (16.3 h mg mL1). Thus,
plasma pharmacokinetics show that cisplatin is retained in the
circulation for longer when administered as cisplatin@CB[7]
rather than as the free drug, supporting the suggestion that
CB[7] protects the drug from degradation. This increased exposure
could explain the increased cytotoxic activity observed in vivo in
the cisplatin resistant tumour xenograft.
Fig. 4 Growth of (A) cisplatin sensitive A2780 and (B) cisplatin resistant
A2780/cp70 human ovarian tumour xenografts following intraperitoneal
injection on day 0 of saline (K), CB[7] at 250 mg kg1 (J), free cisplatin
at 6 mg kg1 (.), and cisplatin@CB[7] at 34 mg kg1 (n, equivalent
cisplatin dose of 6 mg kg1). Results are the mean  SEM of six mice.
Fig. 5 (A) Levels of platinum measured in mouse plasma collected at
various times up to 24 hours after a single i.p. bolus dose of either
free cisplatin (6 mg kg1;K) or cisplatin@CB[7] at 34 mg kg1 (J).
(B) Levels of platinum measured in mouse plasma as in (A) over the
ﬁrst hour after drug administration and also including results for
cisplatin administered at 8 mg kg1 (.).
Table 3 Comparative pharmacokinetic parameters of intraperitoneal
injection of free cisplatin or cisplatin@CB[7] over a period of 24 hours
Pharmacokinetic parameters Cisplatin Cisplatin@CB[7]
Cmax/mg mL
1 16.2 10.4
Tmax/min 5 5
AUC0–24/h mg mL
1 16.3 28.8
Table 4 Short- and mid-term comparative pharmacokinetic para-
meters of intraperitoneal injection of free cisplatin, at both high and
normal doses, or cisplatin@CB[7]
Pharmacokinetic
parameters
Cisplatin
(6 mg kg1)
Cisplatin
(8 mg kg1)
Cisplatin@CB[7]
(34 mg kg1)
Cmax/mg mL
1 16.2 19.3 10.4
Tmax/min 5 3 5
AUC0–1/h mg mL
1 4.2 4.9 4.8
AUC0–6/h mg mL
1 7.6 10.6 13.2
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Measurements of tissue and tumour levels of platinum show
that the increased exposure increases the platinum levels in
general and that there is no improved tumour selectivity upon
encapsulation within CB[7] (Fig. 6). This is not unexpected
since the encapsulation does not incorporate a targeting
moiety and CB[7] is probably too small (o1 nm in diameter)
to exploit the enhanced permeability and retention eﬀect. We
were not able to increase the dose of cisplatin@CB[7] beyond
34 mg kg1. This may be explained by the observation that
the AUC0–1, a measure of the drug exposure during the ﬁrst
hour after administration, is similar for cisplatin at 8 mg kg1
(4.9 h mg mL1) and cisplatin@CB[7] (4.8 h mg mL1),
compared to that of free drug at 6 mg kg1 (4.2 h mg mL1).
Platinum levels were also measured in tissues taken from
tumour bearing mice at one, four and six hours after injection of
either free cisplatin (6 mg kg1) or cisplatin@CB[7] (34 mg kg1).
Levels in the liver, kidneys and tumours (A2780 and A2780/
cp70) were consistently higher after injection of cisplatin@CB[7]
than for free cisplatin, but this diﬀerence did not always reach
statistical signiﬁcance (Fig. 6). Although liver platinum levels
were higher after injection of cisplatin@CB[7] compared to free
cisplatin at one hour, they were similar after four hours and
signiﬁcantly higher after injection of free cisplatin at six hours
(Fig. 6A).
Conclusions
Regardless of the mechanism of action, this positive in vivo
result has implications for the further testing and evaluation of
not just cucurbituril-based drug delivery vehicles, but for other
macrocycles and polymers as well. Previously our group and
others have concluded that when no change in the in vitro
cytotoxicity is observed upon encapsulation of a platinum-based
drug or attachment of a platinum drug to a nanoparticle, then
the host–guest complexes formed are probably not going to
have better in vivo activity compared with the free drug.38,39
Our results here demonstrate otherwise and indicate that
in vitro results, whether good, bad or unchanged from that
of the free drug, may not be suﬃcient to determine whether the
vehicle will improve the delivery of the platinum drug in
question. Overall, our results demonstrate that CB[7], and
possibly other sized cucurbit[n]urils, may have utility in the
treatment of drug-resistant human cancers and warrant
further investigation. One area for further development is to
attempt to reduce the rate of release of the encapsulated drug
into circulation in order to reduce the initial drug exposure
and thus allow increased doses of the drug.
Methods
Preparation of cisplatin@CB[7]
Cisplatin (Sigma-Aldrich) and CB[7]40 were stirred together in
hot water until dissolved, then stirred for a further 3 h before
being either freeze dried or rotary evaporated to dryness. The
water content of the cisplatin@CB[7] complex was then
determined by elemental analysis and found to be between
5 and 13 water molecules per batch. These waters of crystallisation
were taken into account when calculating the molecular mass of
cisplatin@CB[7] and the subsequent concentrations of each batch
in solution before administration.
Molecular modeling
The geometry optimisations were performed by using the
spin-polarised DFT implemented in the Dmol3 package. The
package is for an accurate and eﬃcient density functional
calculation where a rapidly convergent 3D numerical integration
scheme for molecules is used. The exchange–correlation interaction
was treated within the generalised gradient approximation (GGA)
in which the Becke exchange functional and the Lee–Yang–Parr
correlation functional (BLYP) were used. In the electronic structure
calculations, eﬀective core potential treatment with a double-
numerical basis plus polarised functions (DNPs) was chosen.
Cell lines
A2780/cp70 is an in vitro derived cisplatin resistant variant of
the ovarian cancer cell line A2780 originally obtained from
Dr R.F. Ozols (Fox Chase Cancer Centre, Philadelphia, PA).
A second in vitro derived cisplatin resistant variant, MCP1, was
derived in house.41 Cells were grown in RPMI1640 supplemented
with glutamine (2 mm) and FCS (10%). A2780/cp70 and MCP1
are mismatch repair deﬁcient and do not express MLH1 due to
hypermethylation of the hmlh1 gene promoter.41
Drug sensitivity in vitro
Drug sensitivity was determined by a tetrazolium dye-based
microtitration assay.42 Cells were plated out in 96 well plates
at a density of 300–1000 cells per well and allowed to attach
and grow for 2 days. Cells were exposed to the drug at a range
of concentrations for 24 hours and then the medium was
replaced with drug free medium for further 3 days. On the
ﬁnal day MTT (50 mL of a 5 mg mL1 solution) was added to
Fig. 6 Levels of platinum measured in (A) liver, (B) kidney,
(C) A2780 tumours and (D) A2780/cp70 tumours, collected at one,
four and six hours after a single i.p. bolus dose of either free cisplatin
(6 mg kg1; black bars) or cisplatin@CB[7] (34 mg kg1; grey bars).
Signiﬁcant diﬀerences between free cisplatin and cisplatin@CB[7] are
shown (*P o 0.01, **P o 0.004).
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200 mL of medium in each well and plates were incubated
at 37 1C for 4 h in the dark. The medium and MTT were then
removed and the MTT-formazan crystals dissolved in 200 mL
DMSO. Glycine buﬀer (25 mL per well, 0.1 M, pH 10.5) was
added and the absorbance measured at 570 nm in a multiwell
plate reader. A typical dose–response curve consisted of 8 drug
concentrations and 4 wells were used per drug concentration.
Results are expressed in terms of the drug concentration required
to kill 50% of the cells (IC50) estimated as the absorbance value
equal to 50% of that of the control untreated wells.
Induction of p53 and apoptosis
Cells were plated at a density of 105 cells in a 25 cm2 ﬂask and
allowed to attach and grow for 48 h. Drug was added at a
range of concentrations for 24 h. Both adherent cells and those
in the medium were harvested and washed twice with ice cold
PBS. They were resuspended in 200 mL of lysis buﬀer (50 mM
Hepes pH 7.0, 250 mM NaCl, 0.5% NP-40) supplemented
with protease inhibitors (‘Complete’ from Roche Diagnostics
Ltd, Lewes, UK) and incubated on ice for 20 min. Samples
were centrifuged at 12 000 g for 5 min at 4 1C to remove debris.
Proteins were separated on 4–12% Bis–Tris gels with MOPS
SDS running buﬀer. The ‘‘Novex Xcell II’’ blotting apparatus
(Invitrogen) was used to transfer proteins onto an Immobilon
PVDF membrane (Millipore). The membrane was blocked for
1 h in Tris-buﬀered saline containing 0.02% Tween 20 and 5%
powdered milk and then incubated overnight at 4 1C with the
primary antibody (anti-p53, Novocastra clone D-01 from
Leica Biosystems Ltd and anti-PARP, BD Biosciences). The
membrane was then washed and incubated for 1 hour at room
temperature with the secondary antibody (sheep anti-mouse
HRP, Amersham). After washing, protein bands were visualised
by enhanced chemiluminescence (ECL, Amersham).
Human tumour xenografts
Animal studies were carried out under an appropriate United
KingdomHome Oﬃce Project License and all work conformed to
the UKCCRGuidelines for the welfare of animals in experimental
neoplasia.Monolayer cultures were harvested with trypsin–EDTA
and resuspended in PBS. For the A2780 and A2780/cp70
xenografts about 107 cells were injected subcutaneously into
the right ﬂank of athymic nude mice (CD1 nu/nu mice from
Charles River). After 7 to 10 days when the mean tumour
diameter was at Z 0.5 cm, animals were randomized in groups
of 6 for experiments. A standard sterile clinical formulation of
cisplatin was used (Western Inﬁrmary Pharmacy, Glasgow).
Mice were treated i.p. with CB[7] (250 mg kg1), cisplatin
(6 mg kg1) or cisplatin@CB[7] (34 mg kg1 equivalent to
6 mg kg1 cisplatin). Mice were weighed daily and tumour
volumes were estimated by calliper measurements assuming
spherical geometry (volume = d3  p/6).
Pharmacokinetics
Tumour bearing mice were treated with either cisplatin or
cisplatin@CB[7] as above. Blood, liver, kidney and tumour
were sampled at various times. Blood was collected by cardiac
puncture and samples were placed into ice cold EDTA tubes
and centrifuged at 1500 g for 10 min at 4 1C. Plasma was removed
and stored at70 1C until analysis. Tissues were dissected rapidly
and snap frozen in liquid nitrogen and stored at 70 1C until
analysis. They were then thawed, weighed and homogenised in
PBS (1 mg tissue per mL PBS). Tissue and plasma samples
were incubated overnight at 65 1C with nitric acid (1 mL
homogenate + 9 mL nitric acid (OPTIMA 68%); 1 volume
plasma : 1 volume nitric acid). The samples were then diluted
with water–0.1% Triton-X100 to a ﬁnal concentration of
1% acid. The platinum content of samples was determined
by ICP-MS. Pharmacokinetic parameters were determined
by non-compartmental analysis (WinNonLin Version 4.0 software,
Pharsight, Mountain View, USA).
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